ABOUT OCULAR ALLERGY ITCH

Allergic conjunctivitis is a commonplace challenge

 

Ocular itch is the hallmark symptom of allergic conjunctivitis5-7

PAZEO® Solution is indicated for the treatment of ocular itching associated with allergic conjunctivitis8

Ocular itch is prevalent

More than 70% of Americans with allergies report ocular symptoms9

 

Interviews were conducted online among a sample of 1,622 adults, 18 years of age and older who suffer from respiratory allergies (hay fever, pollen, grasses, trees, ragweed, dust, dust mites, mold, cats/dogs, pollution, smoke) and had used allergy oral medications, eye drops, and/or nasal sprays, either Rx or OTC, during the previous 12 months. Interviewing was conducted from November 14 - December 13, 2013.10

INDICATION AND DOSING

PAZEO® Solution is indicated for the treatment of ocular itching associated with allergic conjunctivitis. The recommended dosage is to instill one drop in each affected eye once a day. 

IMPORTANT SAFETY INFORMATION

As with any eye drop, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle to prevent contaminating the tip and solution. Keep bottle tightly closed when not in use. 

Patients should not wear a contact lens if their eye is red. PAZEO® Solution should not be used to treat contact lens-related irritation. The preservative in PAZEO® Solution, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least five minutes after instilling PAZEO® Solution before they insert their contact lenses. 

The most commonly reported adverse reactions in a clinical study occurred in 2%-5% of patients treated with either PAZEO® Solution or vehicle. These events were blurred vision, dry eye, superficial punctate keratitis, dysgeusia, and abnormal sensation in eye. 

For additional information on PAZEO® Solution, please click here to view the full Prescribing Information.

*Terms and Conditions:

Limitations apply. For commercially insured patients. Up to a $125 cap per bottle. Patient will be responsible for any co-pay once limit per bottle is reached. This offer is not valid under Medicare, Medicaid, or any other federal or state program. Not valid for cash-paying patients. Novartis reserves the right to rescind, revoke, or amend this program without notice. Offer expires 12/31/2017.

References: 1. Friedlaender MH. Ocular allergy. Curr Opin Allergy Clin Immunol. 2011;11 (5):477-482. 2. Wong AH, Barg SS, Leung AK. Seasonal and perennial allergic conjunctivitis. Recent Pat Inflamm Allergy Drug Discov. 2009;3(2):118-127. 3. Miraldi Utz V, Kaufman AR. Allergic eye disease. Pediatr Clin North Am. 2014;61(3):607-620. 4. Singh K, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988-1994. J Allergy Clin Immunol. 2010;126:778-783. 5. Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol. 2005;115(1):118-122. 6. Bielory L, Meltzer EO, Nichols KK, Melton R, Thomas RK, Bartlett JD. An algorithm for the management of allergic conjunctivitis. Allergy Asthma Proc. 2013;34(5):408-420. 7. Leonardi A. The central role of conjunctival mast cells in the pathogenesis of ocular allergy. Curr Allergy Asthma Rep. 2002;2(4):325-331. 8. PAZEO® [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2016. 9. Abelson MB, McLaughlin JT, Gomes PJ. Antihistamines in ocular allergy: are they all created equal? Curr Allergy Asthma Rep. 2011;11(3):205-211. 10. The 2013 US Study of Allergies. Multi-sponsor Surveys, Inc.; Princeton, New Jersey. January 2014. 

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION & DOSING

PAZEO®Solution is indicated for the treatment of ocular itching associated with allergic conjunctivitis. The recommended dosage is to instill one drop in each affected eye once a day. 

IMPORTANT SAFETY INFORMATION

As with any eye drop, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle to prevent contaminating the tip and solution. Keep bottle tightly closed when not in use. 

Patients should not wear a contact lens if their eye is red. PAZEO® Solution should not be used to treat contact lens-related irritation. The preservative in PAZEO®Solution, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least five minutes after instilling PAZEO® Solution before they insert their contact lenses. 

The most commonly reported adverse reactions in a clinical study occurred in 2%-5% of patients treated with either PAZEO®Solution or vehicle. These events were blurred vision, dry eye, superficial punctate keratitis, dysgeusia, and abnormal sensation in eye. 

For additional information on PAZEO® Solution, please click here to view the full Prescribing Information.

*Terms and Conditions:

Limitations apply. For commercially insured patients. Up to a $125 cap per bottle. Patient will be responsible for any co-pay once limit per bottle is reached. This offer is not valid under Medicare, Medicaid, or any other federal or state program. Not valid for cash-paying patients. Novartis reserves the right to rescind, revoke, or amend this program without notice. Offer expires 12/31/2017.

References: 1. Friedlaender MH. Ocular allergy. Curr Opin Allergy Clin Immunol. 2011;11 (5):477-482. 2. Wong AH, Barg SS, Leung AK. Seasonal and perennial allergic conjunctivitis. Recent Pat Inflamm Allergy Drug Discov. 2009;3(2):118-127. 3. Miraldi Utz V, Kaufman AR. Allergic eye disease. Pediatr Clin North Am. 2014;61(3):607-620. 4. Singh K, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988-1994. J Allergy Clin Immunol. 2010;126:778-783. 5. Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol. 2005;115(1):118-122. 6. Bielory L, Meltzer EO, Nichols KK, Melton R, Thomas RK, Bartlett JD. An algorithm for the management of allergic conjunctivitis. Allergy Asthma Proc. 2013;34(5):408-420. 7. Leonardi A. The central role of conjunctival mast cells in the pathogenesis of ocular allergy. Curr Allergy Asthma Rep. 2002;2(4):325-331. 8. PAZEO® [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2016. 9. Abelson MB, McLaughlin JT, Gomes PJ. Antihistamines in ocular allergy: are they all created equal? Curr Allergy Asthma Rep. 2011;11(3):205-211. 10. The 2013 US Study of Allergies. Multi-sponsor Surveys, Inc.; Princeton, New Jersey. January 2014.